SINT
Sintx Technologies, Inc.3.5700
+0.0800+2.29%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
13.75MP/E (TTM)
-Basic EPS (TTM)
-3.74Dividend Yield
0%Recent Filings
8-K
8-K
Warrant inducement nets $3.8M
SINTX Technologies inked an inducement deal on September 8, 2025, coaxing holders to exercise existing warrants for 1,099,431 shares at $3.32 each, netting ~$3.8 million in gross proceeds before fees. In exchange, the company issues new warrants for 1,649,147 shares at $4.79, exercisable over 5.5 years, while locking out variable rate deals for a year to steady the capital stack. Shares outstanding jump to 3,950,388 post-close on September 9. Funds fuel general corporate needs, but closing hinges on conditions.
8-K
CFO appointment and plan approval
SINTX Technologies appointed Kevin Trask as CFO on September 4, 2025, boosting his salary to $300,000 annually with a potential 35% bonus and 20,000 restricted stock units vesting over 2.5 years. At the same annual meeting, stockholders approved the 2025 Equity Incentive Plan and re-elected directors Robert Mitchell and Chris Lyons. This internal shift bolsters financial leadership amid ongoing operations.
10-Q
Q2 FY2025 results
SINTX Technologies posted Q2 revenue of $151K, down 82% y/y from $859K, as the firm sheds low-margin OEM contracts to chase biomedical upside; six-month totals fell 66% y/y to $520K, yet operating losses narrowed 2% y/y to $2.7M thanks to 19% lower expenses from workforce cuts and TA&T sale. Gross margins held at 38%, but net loss widened 5% y/y to $2.3M, driven by a $0.5M swing in derivative fair-value gains versus last year. Cash climbed to $4.3M on $4.1M financing inflows, offsetting $3.7M operating burn; debt sits light at $109K in short-term insurance notes. Closed Sinaptic Surgical asset buy on July 1 for warrants and stock, eyeing surgical tools. Strategic pivot sharpens focus. Regulatory hurdles could stall implant clearances.
8-K
SINTX submits FDA 510(k) for foot implants
SINTX Technologies submitted a 510(k) premarket notification to the FDA on July 22, 2025, for its silicon nitride osteotomy wedges targeting the foot and ankle reconstruction market. These implants leverage the material's pro-osteogenic, antimicrobial, and radiolucent properties to enhance fusion, reduce infections, and improve imaging over traditional options like PEEK or titanium. Backed by over a decade of clinical data from 50,000 spinal implants, the platform promises strong adoption. Yet commercialization risks loom large.
ADMT
ADM Tronics Unlimited, Inc.
0.11+0.00
MDNC
MEDINOTEC INC
5.00+0.00
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NXL
Nexalin Technology, Inc.
0.81-0.01
SENS
Senseonics Holdings, Inc.
6.62-0.17
SGHT
Sight Sciences, Inc.
8.39+0.08
SIBN
SI-BONE, Inc.
19.42+1.01
SRDX
Surmodics, Inc.
42.98+0.00
SYK
Stryker Corporation
351.69-3.62
SYNX
Silynxcom Ltd.
0.78-0.07